B.J. Rimel

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt et al. · New England Journal of Medicine · 2016 · 2.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

Joyce F. Liu, William T. Barry, Michael J. Birrer et al. · The Lancet Oncology · 2014 · 584 citations · Full text

Medicine, Gynecology, Oncology +16

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

Kathleen N. Moore, Angeles Alvarez Secord, Melissa A. Geller et al. · The Lancet Oncology · 2019 · 537 citations

Medicine, Oncology, Pharmacotherapy +10

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

J.F. Liu, William T. Barry, Michael J. Birrer et al. · Annals of Oncology · 2019 · 189 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients

Gillian Gresham, Andrew Hendifar, Brennan Spiegel et al. · npj Digital Medicine · 2018 · 176 citations · Full text

Pharmacy, Oncology, Health Assessment +16